BOT 4.35% 36.0¢ botanix pharmaceuticals ltd

Ann: Trading Halt, page-33

  1. 1,022 Posts.
    lightbulb Created with Sketch. 436
    I think it's unfair to compare the two at this stage, Incannex has only done invitro lab studies, and one Australian Phase 2 trial. Trials are expensive, even small ones. I was a holder in Incannex, sold out at the peak, but will be back in one day.
    Last edited by Jonotr0n: 28/10/22
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.